BACKGROUND: Acute promyelocytic leukemia is a subtype of acute myeloid leukemia characterized by the t(15;17). The incidence and prognostic significance of additional chromosomal abnormalities in acute promyelocytic leukemia is still a controversial matter. DESIGN AND METHODS: Based on cytogenetic data available for 495 patients with acute promyelocytic leukemia enrolled in two consecutive PETHEMA trials (LPA96 and LPA99), we analyzed the incidence, characteristics, and outcome of patients with acute promyelocytic leukemia with and without additional chromosomal abnormalities who had been treated with all-trans retinoic acid plus anthracycline monochemotherapy for induction and consolidation. RESULTS: Additional chromosomal abnormalities were observed in 140 patients (28%). Trisomy 8 was the most frequent abnormality (36%), followed by abn(7q) (5%). Patients with additional chromosomal abnormalities more frequently had coagulopathy (P=0.03), lower platelet counts (P=0.02), and higher relapse-risk scores (P=0.02) than their counterparts without additional abnormalities. No significant association with FLT3/ITD or other clinicopathological characteristics was demonstrated. Patients with and without additional chromosomal abnormalities had similar complete remission rates (90% and 91%, respectively). Univariate analysis showed that additional chromosomal abnormalities were associated with a lower relapse-free survival in the LPA99 trial (P=0.04), but not in the LPA96 trial. However, neither additional chromosomal abnormalities overall nor any specific abnormality was identified as an independent risk factor for relapse in multivariate analysis. CONCLUSIONS: The lack of independent prognostic value of additional chromosomal abnormalities in acute promyelocytic leukemia does not support the use of alternative therapeutic strategies when such abnormalities are found.
BACKGROUND:Acute promyelocytic leukemia is a subtype of acute myeloid leukemia characterized by the t(15;17). The incidence and prognostic significance of additional chromosomal abnormalities in acute promyelocytic leukemia is still a controversial matter. DESIGN AND METHODS: Based on cytogenetic data available for 495 patients with acute promyelocytic leukemia enrolled in two consecutive PETHEMA trials (LPA96 and LPA99), we analyzed the incidence, characteristics, and outcome of patients with acute promyelocytic leukemia with and without additional chromosomal abnormalities who had been treated with all-trans retinoic acid plus anthracycline monochemotherapy for induction and consolidation. RESULTS:Additional chromosomal abnormalities were observed in 140 patients (28%). Trisomy 8 was the most frequent abnormality (36%), followed by abn(7q) (5%). Patients with additional chromosomal abnormalities more frequently had coagulopathy (P=0.03), lower platelet counts (P=0.02), and higher relapse-risk scores (P=0.02) than their counterparts without additional abnormalities. No significant association with FLT3/ITD or other clinicopathological characteristics was demonstrated. Patients with and without additional chromosomal abnormalities had similar complete remission rates (90% and 91%, respectively). Univariate analysis showed that additional chromosomal abnormalities were associated with a lower relapse-free survival in the LPA99 trial (P=0.04), but not in the LPA96 trial. However, neither additional chromosomal abnormalities overall nor any specific abnormality was identified as an independent risk factor for relapse in multivariate analysis. CONCLUSIONS: The lack of independent prognostic value of additional chromosomal abnormalities in acute promyelocytic leukemia does not support the use of alternative therapeutic strategies when such abnormalities are found.
Authors: P Bolufer; F Lo Coco; D Grimwade; E Barragán; D Diverio; B Cassinat; C Chomienne; M Gonzalez; D Colomer; M T Gomez; I Marugan; J Román; M D Delgado; J A García-Marco; R Bornstein; J L Vizmanos; B Martinez; J Jansen; A Villegas; J M de Blas; P Cabello; M A Sanz Journal: Haematologica Date: 2001-06 Impact factor: 9.941
Authors: M A Sanz; G Martín; C Rayón; J Esteve; M González; J Díaz-Mediavilla; P Bolufer; E Barragán; M J Terol; J D González; D Colomer; C Chillón; C Rivas; T Gómez; J M Ribera; R Bornstein; J Román; M J Calasanz; J Arias; C Alvarez; F Ramos; G Debén Journal: Blood Date: 1999-11-01 Impact factor: 22.113
Authors: J M Hernández; G Martín; N C Gutiérrez; J Cervera; M T Ferro; M J Calasanz; J A Martínez-Climent; E Luño; M Tormo; C Rayón; J Díaz-Mediavilla; M González; J D González-San Miguel; K Pérez-Equiza; C Rivas; J Esteve; M del C Alvarez; J Odriozola; J M Ribera; M A Sanz Journal: Haematologica Date: 2001-08 Impact factor: 9.941
Authors: M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum Journal: Blood Date: 2000-12-15 Impact factor: 22.113
Authors: D Grimwade; A Biondi; M J Mozziconacci; A Hagemeijer; R Berger; M Neat; K Howe; N Dastugue; J Jansen; I Radford-Weiss; F Lo Coco; M Lessard; J M Hernandez; E Delabesse; D Head; V Liso; D Sainty; G Flandrin; E Solomon; F Birg; M Lafage-Pochitaloff Journal: Blood Date: 2000-08-15 Impact factor: 22.113
Authors: S De Botton ; S Chevret; M Sanz; H Dombret; X Thomas; A Guerci; M Fey; C Rayon; F Huguet; J J Sotto; C Gardin; P Cony Makhoul ; P Travade; E Solary; N Fegueux; D Bordessoule; J San Miguel ; H Link; B Desablens; A Stamatoullas; E Deconinck; K Geiser; U Hess; F Maloisel; S Castaigne; C Preudhomme; C Chomienne; L Degos; P Fenaux Journal: Br J Haematol Date: 2000-12 Impact factor: 6.998
Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: Miguel A Sanz; Guillermo Martín; Marcos González; Angel León; Chelo Rayón; Concha Rivas; Dolors Colomer; Elena Amutio; Francisco J Capote; Gustavo A Milone; Javier De La Serna; José Román; Eva Barragán; Juan Bergua; Lourdes Escoda; Ricardo Parody; Silvia Negri; María J Calasanz; Pascual Bolufer Journal: Blood Date: 2003-10-23 Impact factor: 22.113
Authors: John C Byrd; Krzysztof Mrózek; Richard K Dodge; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Shivanand R Patil; Kathleen W Rao; Michael S Watson; Prasad R K Koduru; Joseph O Moore; Richard M Stone; Robert J Mayer; Eric J Feldman; Frederick R Davey; Charles A Schiffer; Richard A Larson; Clara D Bloomfield Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: Robert E Gallagher; Barry K Moser; Janis Racevskis; Xavier Poiré; Clara D Bloomfield; Andrew J Carroll; Rhett P Ketterling; Diane Roulston; Esther Schachter-Tokarz; Da-Cheng Zhou; I-Ming L Chen; Richard Harvey; Greg Koval; Dorie A Sher; James H Feusner; Martin S Tallman; Richard A Larson; Bayard L Powell; Frederick R Appelbaum; Elisabeth Paietta; Cheryl L Willman; Wendy Stock Journal: Blood Date: 2012-06-25 Impact factor: 22.113
Authors: Eva Barragán; Pau Montesinos; Mireia Camos; Marcos González; Maria J Calasanz; José Román-Gómez; Maria T Gómez-Casares; Rosa Ayala; Javier López; Óscar Fuster; Dolors Colomer; Carmen Chillón; María J Larrayoz; Pedro Sánchez-Godoy; José González-Campos; Félix Manso; Maria L Amador; Edo Vellenga; Bob Lowenberg; Miguel A Sanz Journal: Haematologica Date: 2011-06-17 Impact factor: 9.941
Authors: Inaam Bashir Hassan; Mariam R Al Zaabi; Arif Alam; Mohammed Jawad Hashim; Martin S Tallman; Jorgen Kristensen Journal: Int J Hematol Date: 2017-03-14 Impact factor: 2.490
Authors: S Kayser; J Krzykalla; M A Elliott; K Norsworthy; P Gonzales; R K Hills; M R Baer; Z Ráčil; J Mayer; J Novak; P Žák; T Szotkowski; D Grimwade; N H Russell; R B Walter; E H Estey; J Westermann; M Görner; A Benner; A Krämer; B D Smith; A K Burnett; C Thiede; C Röllig; A D Ho; G Ehninger; R F Schlenk; M S Tallman; M J Levis; U Platzbecker Journal: Leukemia Date: 2017-03-21 Impact factor: 11.528
Authors: Xavier Poiré; Barry K Moser; Robert E Gallagher; Kristina Laumann; Clara D Bloomfield; Bayard L Powell; Gregory Koval; Kabir Gulati; Nicholas Holowka; Richard A Larson; Martin S Tallman; Frederick R Appelbaum; Dorie Sher; Cheryl Willman; Elisabeth Paietta; Wendy Stock Journal: Leuk Lymphoma Date: 2014-02-04